Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Alphamab Oncology (9966)

Hong Kong
Currency in HKD
Disclaimer
4.53
-0.11(-2.37%)
Closed
Fair Value
Unlock Value
Day's Range
4.534.75
52 wk Range
3.8117.34
Bid/Ask
4.52 / 4.53
Prev. Close
4.64
Open
4.64
Day's Range
4.53-4.75
52 wk Range
3.81-17.34
Volume
1,811,000
Average Volume (3m)
3,452,674
1-Year Change
-67.64%
Shares Outstanding
964,843,807
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
5.48
Upside +20.97%
How do you feel today about 9966?
Vote to see community's results!
or

Alphamab Oncology Company Profile

Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for neoadjuvant treatment of HER2-positive breast cancer and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company’s product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial for auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that is in phase III clinical trials for advanced solid tumors with deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III clinical trials for biliary tract cancer. In addition, its product pipeline also includes KN052, a PD-L1/OX40 bispecific antibody, which is in phase I clinical trial for the treatment of advanced solid tumors; and JSKN003, a biparatopic HER2-targeting antibody-drug conjugate that is in phase Ia/Ib clinical trial for the treatment of advanced malignant solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People’s Republic of China.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.